Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 104Lymphoma 78Lung Neoplasms 68Colorectal Neoplasms 61Carcinoma, Non-Small-Cell Lung 60Rectal Neoplasms 58Leukemia 56Colonic Neoplasms 56Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Central Nervous System Neoplasms 39Lymphoma, Large B-Cell, Diffuse 38Prostatic Neoplasms 35Ovarian Neoplasms 33Melanoma 33Lymphoma, Non-Hodgkin 33Head and Neck Neoplasms 32Burkitt Lymphoma 31Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Ovarian Epithelial 30Lymphoma, Large-Cell, Immunoblastic 28Kidney Neoplasms 28Multiple Myeloma 26Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 25Carcinoma, Renal Cell 25Sarcoma 24Neoplasms, Plasma Cell 24Leukemia, Myeloid, Acute 24Hodgkin Disease 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NIH × Dermatologic Complications × Clear all
NCT00498992 2013-09-20

Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

National Cancer Institute (NCI)

Phase NA Unknown
20 enrolled
Other solid neoplasm

Dermatologic Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡